News & Media

28 November 2025

N2CR is moving into an exciting new phase. Since its establishment in 2020, N2CR has flourished under the leadership of ...

9 September 2025

Acute myeloid leukaemia (AML) is a fast-growing blood cancer that often becomes resistant to standard treatments. This r...

3 September 2025

Treatment of relapsed/refractory non-Hodgkin’s lymphoma (R/R-NHL) remains one of the most difficult challenges in haem...

31 August 2025

Sorafenib is a first-line therapy used to treat advanced liver cancer, but its effectiveness is often reduced due to res...

13 August 2025

Venetoclax (VEN) is a targeted therapy used to treat chronic lymphocytic leukemia and acute myeloid leukemia. It works b...

5 August 2025

N2CR had its 3rd annual retreat at Grand Copthorne Waterfront Hotel on 25 July 2025. From inspiring discussions and exch...

21 July 2025

A Phase I clinical trial, led by N2CR clinician-scientist A/Prof David Tan, tested a new drug combination—Selinexor, n...

20 June 2025

Multiple myeloma (MM) is a type of blood cancer that originates from abnormal plasma cells in the bone marrow, leading t...

9 April 2025

Multiple primary cancers (MPC) often indicate a hereditary cancer predisposition syndrome. In a study led by Prof Lee So...